Research boost to improve outcomes for melanoma patients
15 July 2021
Melanoma Institute Australia (MIA) researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
NHMRC Clinical Trials and Cohort Studies Grant
MIA has received a National Health and Medical Research Council (NHMRC) Clinical Trials and Cohort Studies Grant of $1 million over five years for the ABC-X study: Anti-PD 1 Brain Collaboration + Radiotherapy Extension.
The purpose of this research study is to determine whether administering radiotherapy to melanoma brain tumours, in combination with 2 immunotherapy drugs (nivolumab and ipilimumab), will be more effective than treating brain tumours with immunotherapy alone. Patients in this trial will be randomly assigned to 1 of 2 treatment groups. Group 1 will receive radiotherapy to their melanoma brain lesion(s), combined with immunotherapy. Group 2 will receive immunotherapy treatment alone.
This study is currently recruiting at Melanoma Institute Australia, Westmead Hospital, Calvary Mater Newcastle Hospital, Princess Alexandra Hospital Queensland, Peter MacCallum Cancer Centre and will soon be opening at Royal Adelaide Hospital, Alfred Hospital and Oslo University Hospital Norway
MRFF Efficient Use of Existing Medicines Grant
MIA also received a Medical Research Future Fund (MRFF) Efficient Use of Existing Medicines Grant of $2 million over four years for the NADINA Phase 3 trial comparing response driven neo-adjuvant combination of ipilimumab + nivolumab versus adjuvant nivolumab
Standard care for melanoma spread to lymph nodes is surgery followed by one year of drug treatment to prevent recurrence. A drug used now in many cancers, immunotherapy, cost Australia $688 million in 2020. This study will test a safe and cost-effective way to prevent recurrence with just 6 weeks of immunotherapy before surgery, known as neo-adjuvant therapy. If the tumour is destroyed, major surgery and more drug therapy can be avoided. A shorter course of drug therapy will reduce healthcare costs by nearly 50%.
We plan to offer this study across four Australian sites and also in the Netherlands.
This grant funding helps facilitate MIA’s world-leading researchers to continue their ground-breaking work in melanoma research in order to improve outcomes for patients and achieve our goal of zero deaths from melanoma this decade.
Melanoma Institute Australia is affiliated with The University of Sydney.
Sydney Health Partners' goal is to ensure world class research is successfully implemented & scaled-up to benefit patients & wider society.
Promising young MIA researcher conferred with University of Sydney PhD.
Jana Pittman and Melinda Gainsford-Taylor urge Australians to be sun-safe and check their skin as they join the Game On Mole campaign in support of their much-loved coach
Cited an incredible 427 times around the world, showing its vital role in improving outcomes for people with advanced melanoma.
Honouring the exceptional impact of his work on communities around the world.
MIA's Co-Medical Directors receive University of Sydney's Vice-Chancellor's Award for Outstanding Research
Awarded for their life-saving discoveries transforming melanoma patient care.
National day of action called amidst fears COVID lockdowns have deterred patients from seeking potentially life-saving medical treatment
Recognising her pioneering work in immunotherapy in melanoma, transforming the care of patients worldwide.
Clinicians and researchers from across Australia and beyond united online, bringing the AMC2021 conference theme of Promising Futures to life.
Melanoma Institute Australia is proud to announce that the Nine Network’s Peter Overton AM has joined us as a National Ambassador.
MIA is proud to announce that five of our researchers have been named on the Clarivate Annual Highly Cited Researchers™ 2021 list.
New research shows routine skin checks by a health professional, coupled with checking your own skin, are vital in saving lives from melanoma.
With new patient figures indicating people may have deferred skin checks during the pandemic our Game On Mole campaign is more important than ever.
We are excited to announce a return to our much-loved physical Melanoma March events in March 2022!
Read more about the wonderful MIA community fundraising initiatives held recently.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Over two fun, yet challenging, days in September an intrepid group of riders and crew successfully completed the annual Melanoma Bike Bash in WA!
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
Three MIA researchers at University of Sydney received grants to further their important melanoma research.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.